News | December 30, 2021
Sanofi loses appeal in the US over Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Biocon Biologics and Viatris co-developed the products
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
